SYSTEMIC INFLAMMATORY INDICES IN PATIENTS WITH MALIGNANT GLIOMAS AND EFFECTS OF PLATELET SECRETOME IN VITRO
DOI:
https://doi.org/10.15407/exp-oncology.2023.04.409Keywords:
malignant glioma, platelets, secretome, U251 cell line, mitotic index, TGF-β1, systemic inflammatory indexesAbstract
Background. To date, no significant clinical progress has been achieved in the treatment of brain malignant gliomas (MG), and the active search for non-invasive circulating biomarkers continues. The prognostic significance of the ratio of the main peripheral blood cell populations of patients with MG is evaluated. Considerable attention is paid to the secretome of platelets (Pt) of peripheral blood. Aim. To evaluate the indicators of the peripheral blood cell population ratios in patients with brain MG and to study the influence of the secretome of Pt (SPt) of the peripheral blood of patients with brain MG in cell cultures in vitro. Materials and Methods. We studied samples of peripheral blood from patients with glioma CNS WHO grade G2 (n = 5), G3 (n = 12), and G4 (n = 20). The peripheral blood cell counts were analyzed in the preoperative period on an automatic hematology analyzer. The in vitro study of SPt was performed on the U251 human glioblastoma cell line cultured with SPt from MG patients or SPt pre-incubated with anti-TGF-β1 antibody. Cell cultures were observed for 72 h, and mitotic index (MI) was calculated. Results. In MG patients, the count of peripheral blood leukocytes and neutrophils increased (p < 0.05). The neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII) increased by 2—3 times compared to control. Nevertheless, correlation analysis did not reveal significant relationships between quantitative indicators of peripheral blood cells and the tumor malignancy degree in MG patients. The MI in U251 cells increased under the influence of SPt from patients with MG (p < 0.021), correlated with the tumor degree of malignancy (r = 0.246, p = 0.014). Pre-incubation of SPt with anti-TGF-β1 antibody tends to neutralize this promitotic effect. Conclusion. In MG patients, the integral indicators of NLR and SII increased but no significant relationship with the degree of tumor malignancy was found. In U251 cells, promitotic effects of SPt of MG patients partially decreased by anti-TGF-β1 antibody.
References
Fedorenko Z, Michailovich Yu, Goulak L, et al. Cancer in Ukraine, 2020—2021: Incidence, mortality, prevalence and other relevant statistics. Bull Nat Cancer Reg Ukraine. 2022;23. Available at: http://www.ncru.inf.ua/publica- tions/BULL_23/index_e.htm
Ostrom QT, Cioffi G, Waite K, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. Neuro Oncol. 2021;23: iii1-iii105. https://doi.org/10.1093/neuonc/noab200
Low JT, Ostrom QT, Cioffi G, et al. Primary brain and other central nervous system tumors in the United States (2014-2018): A summary of the CBTRUS statistical report for clinicians. Neurooncol Pract. 2022;9:165-182. https://doi.org/10.1093/nop/npac015
Müller L, Tunger A, Plesca I, et al. Bidirectional crosstalk between cancer stem cells and immune cell subsets. Front Immunol. 2020;11:140. https://doi.org/10.3389/fimmu.2020.00140
Dapash M, Hou D, Castro B, et al. The interplay between glioblastoma and its microenvironment. Cells. 2021;10:2257. https://doi.org/10.3390/cells10092257
Alix-Panabières C, Pante, K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem. 2013;59:110-118. https://doi.org/10.1373/clinchem.2012.194258
Crowley E, Di Nicolantonio F, Loupakis F, et al. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10:472-484. https://doi.org/10.1038/nrclinonc.2013.110
Kan LK, Drummond K, Hunn M, et al. Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis. BMJ Neurol Open. 2020;2:e000069. https://doi.org/10.1136/bmjno-2020-000069
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23:1231-1251. https://doi.org/10.1093/neuonc/noab106
van Linde ME, van der Mijn JC, Pham TV, et al. Evaluation of potential circulating biomarkers for predic- tion of response to chemoradiation in patients with glioblastoma. J Neurooncol. 2016;129:221-30. https://doi.org/10.1007/s11060-016-2178-x
Loo HK, Mathen P, Lee J, et al. Circulating biomarkers for high-grade glioma. Biomark Med. 2019;13:161-165. https://doi.org/10.2217/bmm-2018-0463
Ali H, Harting R, de Vries R, et al. Blood-based biomarkers for glioma in the context of gliomagenesis: a system- atic review. Front Oncol. 2021;11:665235. https://doi.org/10.3389/fonc.2021.665235
Bao Y, Yang M, Jin C, et al. Preoperative hematologic inflammatory markers as prognostic factors in patients with glioma. World Neurosurg. 2018;119:e710-e716. https://doi.org/10.1016/j.wneu.2018.07.252.
Saito T, Sugiyama K, Hama S, et al. Prognostic importance of temozolomide-induced neutropenia in glioblas- toma, IDH-wildtype patients. Neurosurg Rev. 2018;41:621-628. https://doi.org/10.1007/s10143-017-0903-3
Koudriavtseva T, Villani V, Lorenzano S, et al. Neutrophil-to-lymphocyte ratio, Factor VIII and Antithrombin III: inflammatory-clotting biomarkers in glioma. EXCLI J. 2021;20:1152-1169. https://doi.org/10.17179/ex-cli2021-3831
Madhugiri VS, Subeikshanan V, Dutt A, et al. Biomarkers of systemic inflammation in patients with glioblastoma: an analysis of correlation with tumour-related factors and survival. Neurol India. 2021;69:894-901. https://doi.org/10.4103/0028-3886.323885
Best MG, Wesseling P, Wurdinger T. Tumor-educated platelets as a noninvasive biomarker source for cancer detection and progression monitoring. Cancer Res. 2018;78:3407-3412. https://doi.org/10.1158/0008-5472.CAN-18-0887
Marx S, Xiao Y, Baschin M, et al. The role of platelets in cancer pathophysiology: focus on malignant glioma.
Cancers (Basel). 2019;11:569. https://doi.org/10.3390/cancers11040569. PMID: 31013620
Michelson AD. Platelets. 3rd ed. London: Academic Press, 2013.
Machlus KR, Thon JN, Italiano JE Jr. Interpreting the developmental dance of the megakaryocyte: a review of the cellular and molecular processes mediating platelet formation. Br J Haematol. 2014;165:227-236. https://doi.org/10.1111/bjh.12758
Sharda A, Flaumenhaft R. The life cycle of platelet granules. F1000Res. 2018;7:236. https://doi.org/10.12688/f1000research.13283.1
Cole BJ, Seroyer ST, Filardo G, et al. Platelet-rich plasma: where are we now and where are we going? Sports Health. 2010;2:203-210. https://doi.org/10.1177/1941738110366385
Sundman EA, Cole BJ, Fortier LA. Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. Am J Sports Med. 2011;39:2135-2140. https://doi.org/10.1177/0363546511417792
Labelle M, Begum S, Hynes RO. Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci USA. 2014;111:E3053-E3061. https://doi.org/10.1073/pnas.1411082111
Gaertner F, Massberg S. Blood coagulation in immunothrombosis-At the frontline of intravascular immunity. Semin Immunol. 2016;28:561-569. https://doi.org/10.1016/j.smim.2016.10.010
Hampton T. Platelets' role in adaptive immunity may contribute to sepsis and shock. JAMA. 2018;319:1311-1312. https://doi.org/10.1001/jama.2017.12859
Huong PT, Nguyen LT, Nguyen XB, et al. The role of platelets in the tumor-microenvironment and the drug resistance of cancer cells. Cancers (Basel). 2019;11:240. https://doi.org/10.3390/cancers11020240
Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. J Hematol Oncol. 2018;11:125. https://doi.org/10.1186/s13045-018-0669-2
Sloan A, Hoffman H, Harris P, et al. Stem-17. The glioma stem cell platelet interaction drives GBM oncoge- nesis identifying a novel therapeutic approach. Neuro Oncol. 2021;23:vi24. https://doi.org/10.1093/neuonc/noab196.091
Pucci F, Rickelt S, Newton AP, et al. PF4 promotes platelet production and lung cancer growth. Cell Rep. 2016;17:1764-1772. https://doi.org/10.1016/j.celrep.2016.10.031
Lana JFSD, Purita J, Paulus C, et al. Contributions for classification of platelet rich plasma — proposal of a new classification: MARSPILL. Regen Med. 2017;12:565-574. https://doi.org/10.2217/rme-2017-0042
Campanella R, Guarnaccia L, Cordiglieri C, et al. Tumor-educated platelets and angiogenesis in glioblastoma: another brick in the wall for novel prognostic and targetable biomarkers, changing the vision from a localized tumor to a systemic pathology. Cells. 2020;9:294. https://doi.org/10.3390/cells9020294
D'Ambrosi S, Nilsson RJ, Wurdinger T. Platelets and tumor-associated RNA transfer. Blood. 2021;137:3181-3191. https://doi.org/10.1182/blood.2019003978
Sol N, In‘t Veld GJG, Vancura A, et al. Tumor-educated platelet RNA for the detection and (pseudo) progression monitoring of glioblastoma. Cell Rep Med. 2020;1:100101. https://doi.org/10.1016/j.xcrm.2020.100101
Chen X, Lin Q, Jiang Y, et al. Identification of potential biomarkers of platelet RNA in glioblastoma by bioinfor- matics analysis. Biomed Res Int. 2022;2022:2488139. https://doi.org/10.1155/2022/2488139
Nilsson RJ, Balaj L, Hulleman E, et al. Blood platelets contain tumor-derived RNA biomarkers. Blood. 2011;118:3680-3683. https://doi.org/10.1182/blood-2011-03-344408
Brehar FM, Arsene D, Brinduse LA, et al. Immunohistochemical analysis of GFAP-δ and nestin in cerebral astro- cytomas. Brain Tumor Pathol. 2015;32:90-98. https://doi.org/10.1007/s10014-014-0199-8
Grube S, Freitag D, Kalff R, et al. Characterization of adherent primary cell lines from fresh human glioblastoma tissue, defining glial fibrillary acidic protein as a reliable marker in establishment of glioblastoma cell culture. Cancer Rep. 2021;4:e1324. https://doi.org/10.1002/cnr2.1324
Venkatesan S, Hoogstraat M, Caljouw E, et al. TP53 mutated glioblastoma stem-like cell cultures are sensi- tive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by com- bined inhibition of mTORC1/2 and Bcl-2. Oncotarget. 2016;7:58435-58444. https://doi.org/10.18632/onco-target.11205
Vonshak A. Chapter 15. Micro-algae: laboratory growth techniques and outdoor biomass production. In: Coombs J, Hall DO, Long SP, Scurlock JMO, eds. Pergamon International Library of Science, Technology, Engineering and Social Studies, Techniques in Bioproductivity and Photosynthesis (Second Edition), Pergamon, 1985: 188-200. https://doi.org/10.1016/B978-0-08-031999-5.50025-X
Liubich, LD, Lisyanyi NI, Malysheva TA, et al. In vitro effects of platelet-derived factors of brain glioma patients on C6 glioma cells. Reg Mech Biosystems. 2019;10:187-196. https://doi.org/10.15421/021928
Di Vito C, Navone SE, Marfia G, et al. Platelets from glioblastoma patients promote angiogenesis of tumor endothelial cells and exhibit increased VEGF content and release. Platelets. 2017;28:585-594. https://doi.org/10.1080/09537104.2016.1247208
Braun A, Anders H-J, Gudermann T, et al. Platelet-cancer interplay: molecular mechanisms and new therapeutic avenues. Front Oncol. 2021;11:665534. https://doi.org/10.3389/fonc.2021.665534
Frei K, Gramatzki D, Tritschler I, et al. Transforming growth factor-β pathway activity in glioblastoma. Oncotar- get. 2015;6:5963-5977. https://doi.org/10.18632/oncotarget.3467
Haemmerle M, Taylor ML, Gutschner T, et al. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat Commun. 2017;8:310-315. https://doi.org/10.1038/s41467-017-00411-z
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
